Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CM336 injection in relapsed or refractory primary systemic light-chain amyloidosis
CTR20252427Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in light-chain amyloidosis, sponsored by Keymed Biosciences. Started Jul 2025; status: active.
02
Drugs
gamgertamig
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20252427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252427.